Recombinant urate oxidase (rasburicase) degrades uric acid to ten times soluble metabolites.[79] Despite rasburicase’s widespread use, Darmon et al[72] reported that TLS occurred in >60% of HR-TLS patients, and half also had AKI. Here, UOX is linked to Tumor Lysis Syndrome.